重复测量脂蛋白(a)摩尔浓度与心血管风险
在UK Biobank 16,017名无亲缘关系个体中,基线及随访脂蛋白(a)摩尔浓度中位4.42年显著相关(Spearman rho=0.96,P<0.0001)。在15,432名参与者中,随访脂蛋白(a)与 incident CAD 风险显著相关(每120 nmol/L HR 1.32,95%CI 1.16-1.50,P=0.0002),但变化值独立于随访值无显著关联(P=0.98)。
要点
- 脂蛋白(a)摩尔浓度在4.42年内高度稳定(rho=0.96)。
- 随访脂蛋白(a)每升高120 nmol/L,CAD风险增加32%。
- 脂蛋白(a)变化值不独立于随访值预测CAD风险。
核心结论
- 在未使用显著改变脂蛋白(a)的治疗时,单次准确测量脂蛋白(a)摩尔浓度即可有效评估CAD风险。
研究设计与样本
- 基于UK Biobank的前瞻性队列分析,评估16,017名无亲缘关系个体重复测量脂蛋白(a)的相关性。
- 在15,432名参与者中使用Cox比例风险模型分析脂蛋白(a)变化与 incident CAD 的关联。
主要发现
- 基线与随访脂蛋白(a)摩尔浓度中位4.42年(IQR 3.69-4.93)显著相关(Spearman rho=0.96,P<0.0001)。
- 不同测量间隔(<3、3-4、4-5、>5年)相关性稳定(rho分别为0.96、0.97、0.96、0.96)。
- 他汀使用与脂蛋白(a)变化关联轻微至中等,但基线≥70 nmol/L者他汀使用与脂蛋白(a)显著升高相关。
- 随访脂蛋白(a)摩尔浓度与 incident CAD 风险显著相关(每120 nmol/L HR 1.32,95%CI 1.16-1.50,P=0.0002)。
- 随访与基线脂蛋白(a)差值独立于随访脂蛋白(a)与 incident CAD 无显著关联(P=0.98)。
临床怎么用
- 在无显著改变脂蛋白(a)的治疗时,单次准确测量脂蛋白(a)摩尔浓度可用于CAD风险分层。
- 基线脂蛋白(a)≥70 nmol/L者使用他汀时需注意脂蛋白(a)可能升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When indicated, guidelines recommend measurement of lipoprotein(a) for cardiovascular risk assessment. However, temporal variability in lipoprotein(a) is not well understood, and it is unclear if repeat testing may help refine risk prediction of coronary artery disease (CAD). OBJECTIVES: The authors examined the stability of repeat lipoprotein(a) measurements and the association between instability in lipoprotein(a) molar concentration with incident CAD. METHODS: The authors assessed the correlation between baseline and first follow-up measurements of lipoprotein(a) in the UK Biobank (n = 16,017 unrelated individuals). The association between change in lipoprotein(a) molar concentration and incident CAD was assessed among 15,432 participants using Cox proportional hazards models. RESULTS: Baseline and follow-up lipoprotein(a) molar concentration were significantly correlated over a median of 4.42 years (IQR: 3.69-4.93 years; Spearman rho = 0.96; P < 0.0001). The correlation between baseline and follow-up lipoprotein(a) molar concentration were stable across time between measurements of <3 (rho = 0.96), 3-4 (rho = 0.97), 4-5 (rho = 0.96), and >5 years (rho = 0.96). Although there were negligible-to-modest associations between statin use and changes in lipoprotein(a) molar concentration, statin usage was associated with a significant increase in lipoprotein(a) among individuals with baseline levels ≥70 nmol/L. Follow-up lipoprotein(a) molar concentration was significantly associated with risk of incident CAD (HR per 120 nmol/L: 1.32 [95% CI: 1.16-1.50]; P = 0.0002). However, the delta between follow-up and baseline lipoprotein(a) molar concentration was not significantly associated with incident CAD independent of follow-up lipoprotein(a) (P = 0.98). CONCLUSIONS: These findings suggest that, in the absence of therapies substantially altering lipoprotein(a), a single accurate measurement of lipoprotein(a) molar concentration is an efficient method to inform CAD risk.
引用
- Trinder M, Paruchuri K, Haidermota S, et al. Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. J Am Coll Cardiol. 2022. PMID: 35177190. doi:10.1016/j.jacc.2021.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。